Back to Search
Start Over
Vertex Pharmaceuticals announces FDA acceptance of triple combination therapy
- Source :
- The Fly. July 2, 2024
- Publication Year :
- 2024
-
Abstract
- Vertex Pharmaceuticals announced that the FDA has accepted its new drug application, or NDA, for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy for people living with cystic fibrosis, or CF, ages [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.799826660